tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Vaxart Adjourns Stockholder Meeting for Vote Solicitation

Story Highlights
Vaxart Adjourns Stockholder Meeting for Vote Solicitation

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Vaxart ( (VXRT) ) has shared an update.

On September 5, 2025, Vaxart, Inc. adjourned its special meeting of stockholders to provide additional time for voting on proposals, including a reverse stock split. The meeting will reconvene on September 19, 2025, and during the adjournment, Vaxart will continue soliciting votes. This decision reflects recent changes in board composition and governance considerations, highlighting the company’s strategic focus on maintaining its Nasdaq listing and engaging with stockholders to maximize value.

The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall score is driven by strong revenue growth and promising vaccine developments, but is significantly hindered by ongoing financial challenges, negative profitability, and technical bearish trends. The stock’s valuation remains unattractive due to negative earnings, and operational uncertainties further weigh on the score.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered in pill form, which allows for storage and shipping without refrigeration and eliminates the risk of needle-stick injuries. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV), marking its first foray into immune-oncology.

Average Trading Volume: 4,523,934

Technical Sentiment Signal: Sell

Current Market Cap: $86.15M

For an in-depth examination of VXRT stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1